Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
109.84
+1.58 (1.46%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 414 employees as of December 31, 2025. The number of employees increased by 131 or 46.29% compared to the previous year.
Employees
414
Change (1Y)
131
Growth (1Y)
46.29%
Revenue / Employee
$524,553
Profits / Employee
-$502,029
Market Cap
7.53B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Mirum Pharmaceuticals | 418 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
RYTM News
- 11 days ago - Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord - TheFly
- 12 days ago - Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire
- 12 days ago - Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo - TheFly
- 13 days ago - Rhythm announces preliminary data from Phase 2 trial of setmelanotide - TheFly
- 14 days ago - Rhythm Pharmaceuticals Transcript: Study result - Transcripts
- 14 days ago - Rhythm Pharmaceuticals Slides: Study result - Filings
- 14 days ago - Rhythm Pharmaceuticals Press release: Study result - Filings
- 14 days ago - Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire